Medeor Therapeutics Stock
Medeor Therapeutics is a biotechnology company that dedicates to dedicates to the development of personalized cellular immunotherapies.
Sign up today and learn more about Medeor Therapeutics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Medeor Therapeutics Stock
Medeor Therapeutics is a biotechnology company that dedicates to the discovery, development and commercialization of transformative and personalized cellular immunotherapies. Its growing team of professionals possesses remarkably deep expertise in cellular immunotherapy and transplantation product development. Its pipeline addresses critical medical needs of the approximately 120,000 annual organ transplant recipients worldwide, including greater than 30,000 annual organ transplant recipients in the US alone. Medeor's product candidates are intended to minimize or eliminate chronic anti-rejection, immunosuppressive drug regimens used by new recipients of living donor transplants as well as those who have received a living donor transplant in the past (i.e., 2nd Chance Therapy). The company holds exclusive worldwide licenses to a series of breakthrough technologies, all discovered at Stanford University. Medeor is headquartered in San Mateo, California.
Funding History
November 2017 | $57.0M |
---|
Management
Co-Founder, President and CEO
Steven Deitcher
Press
patents - Apr, 14 2024
Cellular compositions derived from prior organ donors and methods of …patents - Apr, 14 2024
Methods of analysis of blood from deceased donorspatents - Apr, 14 2024
Methods for treating non-cancerous disorders using hematopoietic cellspatents - Apr, 14 2024
Calcineurin inhibitor to improve cd3+cell survival to thereby facilitate …patents - Apr, 14 2024
Compositions for establishing mixed chimerism and methods of manufacture …